percent) underwent an unplanned reoperation. Most common reasons for unplanned reoperation were hematoma (19.4%), flap failure (19.4%) and a systematic vascular reason (17.7%). Mean time to reoperation was earliest in the hematoma cohort (4.33 ± 6.11 days) and flap failure cohort (4.92 ± 7.37 days). Latest time to reoperation was in the infection cohort (14.00 ± 4.85 days) and dehiscence cohort (13.50 ± 5.57 days). On multivariate logistic regression, independent risk factors for unplanned free flap reoperation (p < 0.05) included an ASA >3 [adjusted OR, 6 CONCLUSION: National data indicates that complication rates are high in head and neck reconstruction for malignancy. Patients with independent risk factors for reoperation should be monitored more closely to reduce the severity of these complications. Identifying common complications, latency between complication and reoperation, personalized patient complication risk, and independent factors that lead to reoperation are critical in identifying complications early and managing them successfully. Development of a clinical risk calculator may help patient decision making by tailoring information on risk of complications. Cross-sex hormone treatment is an established component of management and is required by World Professional Association for Transgender Health guidelines prior to surgical interventions. The impact of hormone replacement therapy in gender congruent individuals on hemostatic outcomes is well-established. Unfortunately, comprehensive understanding of its effects on venous thromboembolism (VTE) risk in the transgender population is lacking.
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METHODS:
A systematic review of the Pubmed, Google Scholar, and EBSCO databases was performed in October 2018. Studies assessing thromboembolic events in transgender patients undergoing cross-sex hormone treatment were included. Review articles, case reports, and studies lacking descriptions of hormone therapies were excluded. Data regarding demographics, hormone therapy, and venous thromboembolism incidence were collected and pooled for analysis. Statistical analysis was performed using a Student's t-test.
RESULTS:
Of 2,948 initial titles, 51 articles were read in their entirety, and 23 were included for pooled analysis. All studies were retrospective in nature. In total, 9,180 transgender patients (6,068 male-to-female and 3,112 female-to-male) underwent cross-sex hormone therapy. Hormone therapies in male-to-female (MTF) patients most commonly consisted of oral or transdermal estrogen formulations with-or-without progestogens. The majority of female-to-male (FTM) patients received intramuscular or oral testosterone. Weighted VTE rates of 2.5% in male-to-female patients (50.6 per 10,000 person-years) and 0.87% (20.7 per 10,000 person-years) in female-to-male patients were observed. When compared to previously published rates in cisgender patients undergoing hormone replacement therapy, MTF patients did not have a significantly risk for VTE (p=0.953) while FTM patients had significantly lower risk for VTE (p >0.001) . Additionally, the data demonstrated a trend towards higher VTE risk in maleto-female patients undergoing oral estrogen treatment compared to transdermal estrogen.
CONCLUSIONS:
Hormone therapy in transgender patients is essential to promote a physiologic state aligned with gender identity. However its potential effects on thrombotic complications must be assessed prior to surgical interventions. Transgender patients may undergo invasive surgeries requiring periods of immobilization in order to complete their transitions. Our analysis suggests that MTF patients undergoing cross-sex hormone therapy are at similar risk for VTE to cis-gender individuals undergoing hormone replacement therapy, and FTM patients may have lower risk. Surgical planning regarding perioperative and postoperative VTE prophylaxis or cessation of hormone therapy should take into account each patient's Caprini risk assessment and the nature of each intervention.
